Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
US6946438B1 · kind B1 · utility
12Cited by
0References
1Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 24, 1999 |
| Grant date | Sep 20, 2005 |
| Priority date | — |
| Expiry date | Sep 24, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/38
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a new means for the treatment of focal ischemic cerebral infarction (ischemic stroke). It has been found that reduction of α2-antiplasmin leads to a significantly smaller focal cerebral infarct size. The invention therefore provides the use of compounds that reduce α2-antiplasmin concentration or activity in vivo, for the preparation of a therapeutical composition for the treatment of focal cerebral ischemic infarction (ischemic stroke).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.